CN1205997C - 人甲状旁腺素在制备增加骨的韧性和劲度以及减少骨折的药剂中的应用 - Google Patents

人甲状旁腺素在制备增加骨的韧性和劲度以及减少骨折的药剂中的应用 Download PDF

Info

Publication number
CN1205997C
CN1205997C CNB998083534A CN99808353A CN1205997C CN 1205997 C CN1205997 C CN 1205997C CN B998083534 A CNB998083534 A CN B998083534A CN 99808353 A CN99808353 A CN 99808353A CN 1205997 C CN1205997 C CN 1205997C
Authority
CN
China
Prior art keywords
bone
pth
day
months
fractures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998083534A
Other languages
English (en)
Chinese (zh)
Other versions
CN1308545A (zh
Inventor
珍妮特·M·霍克
格雷戈里·A·盖克
威拉德·H·德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1205997(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1308545A publication Critical patent/CN1308545A/zh
Application granted granted Critical
Publication of CN1205997C publication Critical patent/CN1205997C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)
CNB998083534A 1998-08-19 1999-08-19 人甲状旁腺素在制备增加骨的韧性和劲度以及减少骨折的药剂中的应用 Expired - Lifetime CN1205997C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097,151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099,746 1998-09-10

Publications (2)

Publication Number Publication Date
CN1308545A CN1308545A (zh) 2001-08-15
CN1205997C true CN1205997C (zh) 2005-06-15

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998083534A Expired - Lifetime CN1205997C (zh) 1998-08-19 1999-08-19 人甲状旁腺素在制备增加骨的韧性和劲度以及减少骨折的药剂中的应用

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP1059933B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE69904918T2 (enExample)
DK (4) DK2907522T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2393200T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU230697B1 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT1059933E (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP2005525312A (ja) * 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
EP1667689A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
JP2012512812A (ja) 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
KR20150021590A (ko) 2009-09-09 2015-03-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
CN103561757B (zh) 2011-06-07 2016-01-06 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
CA3075977C (en) * 2017-09-22 2024-10-29 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT STABILITY
CN119258199A (zh) 2018-10-29 2025-01-07 旭化成制药株式会社 特立帕肽或其盐在骨质疏松症治疗和/或预防剂的制备中的应用
JP7684951B2 (ja) 2019-08-09 2025-05-28 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ，エルエルシー 副甲状腺ホルモン受容体（ｐｔｈｒ１）の調節剤
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
AU4472896A (en) * 1994-12-19 1996-07-10 Beth Israel Hospital Association, The Continuous low-dose administration of parathyroid hormone or its agonist
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
ES2197212T3 (es) * 1994-12-22 2004-01-01 Astrazeneca Ab Preparacion terapeutica para inhalacion que contiene la hormona paratiroidea, pth.
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
ZA988030B (en) * 1997-09-09 1999-03-09 Hoffmann La Roche Fracture healing using pthrp analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
IL138829A0 (en) 2001-10-31
ES2190244T3 (es) 2003-07-16
HUP0101594A2 (hu) 2001-11-28
CA2325371A1 (en) 2000-03-02
CN1308545A (zh) 2001-08-15
PL343595A1 (en) 2001-08-27
DK1769804T3 (da) 2012-10-15
NO323984B1 (no) 2007-07-30
TR200003455T2 (tr) 2001-06-21
DE69904918D1 (de) 2003-02-20
JP2017190332A (ja) 2017-10-19
ES2393200T3 (es) 2012-12-19
EA200001015A1 (ru) 2001-02-26
KR100454207B1 (ko) 2004-10-26
BR9909445A (pt) 2000-12-12
US6977077B1 (en) 2005-12-20
MY129227A (en) 2007-03-30
ES2621653T3 (es) 2017-07-04
CZ301017B6 (cs) 2009-10-14
KR20010072763A (ko) 2001-07-31
HU1200430D0 (hu) 2001-11-28
PT1769804E (pt) 2012-11-13
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
US20050197294A1 (en) 2005-09-08
EA003362B1 (ru) 2003-04-24
ES2549551T3 (es) 2017-11-27
HK1102496A1 (en) 2007-11-23
EP1059933B1 (en) 2003-01-15
AU5575099A (en) 2000-03-14
CZ20004134A3 (cs) 2001-08-15
PT2266598T (pt) 2017-05-02
JP2011021035A (ja) 2011-02-03
EP2266598B1 (en) 2017-02-22
DE15152726T1 (de) 2015-12-10
DK2907522T1 (da) 2015-10-19
ID29039A (id) 2001-07-26
DE69904918T2 (de) 2003-11-13
US7163684B2 (en) 2007-01-16
HU230697B1 (hu) 2017-09-28
NZ507056A (en) 2003-10-31
EP2907522B1 (en) 2017-08-02
PT1059933E (pt) 2003-06-30
HK1030545A1 (en) 2001-05-11
EP1059933A1 (en) 2000-12-20
HK1212602A1 (en) 2016-06-17
NO20072983L (no) 2000-11-24
JP6177718B2 (ja) 2017-08-09
JP2014139220A (ja) 2014-07-31
ES2549551T1 (es) 2015-10-29
ATE231000T1 (de) 2003-02-15
PE20001089A1 (es) 2000-11-04
UA72205C2 (uk) 2005-02-15
AR033639A1 (es) 2004-01-07
CY1113343T1 (el) 2016-06-22
TW576747B (en) 2004-02-21
DK2907522T3 (en) 2017-10-23
PL201688B1 (pl) 2009-04-30
IL138829A (en) 2011-01-31
NO20005947L (no) 2000-11-24
HUP0101594A3 (en) 2002-01-28
WO2000010596A1 (en) 2000-03-02
JP2015028065A (ja) 2015-02-12
EP2266598A1 (en) 2010-12-29
DZ2873A1 (fr) 2003-12-15
DK1059933T3 (da) 2003-04-07
CA2325371C (en) 2004-08-17
NO20005947D0 (no) 2000-11-24
CY1119552T1 (el) 2018-03-07
PT2907522T (pt) 2017-10-23
EP2907522A1 (en) 2015-08-19
HRP20000755A2 (en) 2001-02-28
CO5130020A1 (es) 2002-02-27
DK2266598T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
CN1205997C (zh) 人甲状旁腺素在制备增加骨的韧性和劲度以及减少骨折的药剂中的应用
US7351414B2 (en) Method of reducing the risk of bone fracture
Washimi et al. Effect of intermittent treatment with human parathyroid hormone 1–34 in SAMP6 senescence-accelerated mice
EP1295605A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
EP1769804A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1037333A (en) Method of increasing bone toughness and stiffness and reducing fractures
MXPA00009982A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1212602B (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1102496B (en) Hpth(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
HK1030545B (en) Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050615